Lilly’s Symbyax Requires Prior Authorization Under Massachusetts Medicaid
This article was originally published in The Pink Sheet Daily
Executive Summary
Further drug list changes include prior authorization requirements for Schering-Plough’s Rebetol and Rebetron effective May 3. MassHealth will require prior authorization for J&J’s Duragesic and Purdue’s OxyContin beginning June 1.
You may also be interested in...
Pfizer Caduet Requires Prior Authorization Under Massachusetts Medicaid
MassHealth is also requiring prior authorization for Amgen’s small molecule chronic kidney agent Sensipar and Lilly’s intramuscular formulation of the antipsychotic Zyprexa.
Pfizer Caduet Requires Prior Authorization Under Massachusetts Medicaid
MassHealth is also requiring prior authorization for Amgen’s small molecule chronic kidney agent Sensipar and Lilly’s intramuscular formulation of the antipsychotic Zyprexa.
Schering Generic Ribavirin Carries PEG-Intron Indication; Valeant Will Receive Royalties
Schering generic launches April 8, two days after FDA clears Three Rivers’ and Sandoz’ ribavirin ANDAs. All generics are expected to be priced at a 10% discount to Schering’s Rebetol.